XTL Biopharmaceuticals (NASDAQ:XTLB) Stock Crosses Above 50 Day Moving Average – Time to Sell?

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)’s stock price passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $2.57 and traded as high as $2.89. XTL Biopharmaceuticals shares last traded at $2.89, with a volume of 7,504 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings raised XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 6th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, XTL Biopharmaceuticals currently has an average rating of “Sell”.

XTL Biopharmaceuticals Stock Performance

The stock has a market capitalization of $6.44 million, a P/E ratio of -4.56 and a beta of 1.45. The company has a fifty day simple moving average of $2.58 and a two-hundred day simple moving average of $2.86.

XTL Biopharmaceuticals (NASDAQ:XTLB) last issued its earnings results on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The firm had revenue of ($0.26) million for the quarter.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.